Brief: Arrowhead Pharmaceuticals Files CTA For Investigational Aro-Dimer-PA
07/10/2025 12:55
Oct 7 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS FILES CTA FOR INVESTIGATIONAL ARO-DIMER-PA – THE FIRST DUAL FUNCTIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MIXED HYPERLIPIDEMIA Source text: ID:nBw9vj4TVa Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers